The use of albumin in critical ill patients is a matter of controversy. A large randomized controlled trial reported that albumin was as safe and effective as crystalloid solution for fluid replacement in intensive care unit, although the last one was less expensive. In Surviving Sepsis Campaign International Guidelines there are no preference for crystalloids over colloids. But recently, a retrospective analysis of patients with severe sepsis from SAFE study reported that the use of albumin in these patients would be superior, regarding reduction of mortality. The aim of this study is determine whether the use of albumin improve clinical outcomes in patients with severe sepsis or septic shock.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
360
Lactated Ringer
Albumin 4%
Cancer Institute of Sao Paulo, School of Medicine, University of Sao Paulo
São Paulo, Sao Paulo/SP, Brazil
Mortality in 7 days for any cause
Time frame: day 7
Evaluation of sequential organ failure assessment (SOFA) score
Time frame: from day 1 until day 7 of care in ICU
ICU length of stay
Time frame: day 28
hospital length of stay
Time frame: day 28
ventilator-free days
Time frame: day 28
Needing of renal replacement therapy
Time frame: day 28
days free of vasopressor
Time frame: day 28
Mortality in 28-days
Time frame: 28 days after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.